U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2002

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
EXCHANGE ACT

For the Transition Period from

Commission file number 0-12183

BOVIE MEDICAL CORPORATION

(Exact name of small business issuer as specified in its charter)

Delaware                                                                                                                  No. 11-2644611

(State or other jurisdiction of incorporation or organization)                                                                                                    (IRS— Employer Identification No.)

734 Walt Whitman Rd., Melville, New York 11747

(Address of principal executive offices)

(631) 421-5452

(Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X]     No [  ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:13,204,755

BOVIE MEDICAL CORPORATION

INDEX TO FORM 10-QSB

Contents

Part I.   Financial Information..............................................

        Item 1:       Consolidated Financial Statements:.....................

             Consolidated Balance Sheet - March 31, 2002
                And December 31, 2001........................................
             Consolidated Statements of Operations for the
               three Months Ended March 31,  2002 and 2001...................

             Consolidated Statements of Cash Flows for the
               three Months Ended March 31, 2002 and 2001....................

              Notes to Financial Statements .................................

        Item 2: Management's Discussion and
               Analysis of Financial Conditions and Results of Operations....

Part II.   Other
Information..................................................................

 Item 1:  Legal
Proceedings..................................................................

 Item 2:  Changes in Securities..............................................

 Item 3:  Defaults Upon Senior Securities....................................

 Item 4:  Submission of Matters to Vote of Security Holders..................

 Item 5:  Exhibits and Reports on Form 8-K...................................

INDEPENDENT AUDITORS' REPORT

Board of Directors
Bovie Medical Corp.
Melville, New York

We have reviewed the accompanying balance sheet of Bovie Medical Corp., as of March 31, 2002, and the related statements of operations, and cash flows for the three month ended March 31, 2002 and 2001. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States of America, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with accounting principles generally accepted in the United States of America.

Bloom & Co., LLP.
Hempstead, New York
May 5, 2002

PART I. FINANCIAL INFORMATION
ITEM 1: CONSOLIDATED FINANCIAL STATEMENTS

BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEET
MARCH 31, 2002 AND DECEMBER 31, 2001

                                     Assets

                                           (Unaudited)             (Audited)
                                          March 31, 2002       December 31, 2001

Current assets:

Cash                                       $  315,343             $   578,354
Trade accounts receivable                   1,329,171               1,200,933
Inventories                                 2,496,932               2,419,827
Prepaid expenses                              110,271                 128,045
Deferred tax asset                            386,200                 386,200
Other receivables                                   -                     779
                                            ---------              ----------
Total current assets                        4,637,917               4,714,138

Property and equipment, net                 1,562,254               1,531,658

Other assets:

Repair parts                                  317,613                 300,272
Trade name                                  1,509,662               1,509,662
Patent rights, net                            295,767                 314,691
Deposits                                        8,125                   8,124
Investment - Joint Venture                    200,000                 200,000
                                            ---------               ---------
                                            2,331,167               2,332,749
                                            ---------               ---------

                                           $8,531,338              $8,578,545
                                            =========               =========


The accompanying notes are an integral part of the financial statements.

BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEET
MARCH 31, 2002 AND DECEMBER 31, 2001
(CONTINUED)

                          Liabilities and Stockholders' Equity

                                               (Unaudited)        (Audited)
                                              March 31, 2002   December 31, 2001
Current liabilities:

Accounts payable                           $     486,286          $    373,375
Accrued expense                                  307,844               499,850
Notes payable - current portion                  319,052               228,977
Due to shareholders                               35,523                32,705
                                               ---------             ---------

     Total current liabilities                 1,148,705             1,134,907

Long Term Liabilities                            435,415               443,332

Stockholders' equity:

Preferred Stock, par value $.001
 10,000,000 shares authorized
 0 issued and outstanding                            --                    --
 on March 31, 2002

Common stock par value $.001; 40,000,000
 shares authorized, issued and outstanding
 13,204,755 shares and 13,204,755 shares
      on March 31, 2002 and December 31,
  2001 respectively                               13,274                13,274
Additional paid in capital                    19,815,702            19,814,534
Accumulated deficit                          (12,881,758)          (12,827,302)
                                              ----------            ----------

           Total stockholders' equity          6,947,218             7,000,306
                                              ----------            ----------

       Total liabilities and stockholders'
          equity                             $ 8,531,338            $8,578,545
                                              ==========             =========



The accompanying notes are an integral part of the financial statements.

BOVIE MEDICAL CORPORATION.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED
MARCH 31, 2002 AND 2001
(UNAUDITED)

                                                      2002              2001

Sales                                            $ 3,028,599      $ 2,736,687
Cost of sales                                      1,704,512        1,630,081(1)
                                                   ---------        ---------
Gross profit                                       1,324,087        1,106,606

Costs and expenses:
Research and development                             299,536          130,656
Professional services                                 98,020           81,591
Salaries and related costs                           329,787          328,404
Selling, general and administrative                  639,732          472,791
                                                   ---------        ---------
                                                   1,367,075        1,013,442(1)
                                                   ---------        ---------
Gain (Loss) from operations                      (    42,988)          93,614

Other income (expense):
Interest                                         (    11,468)      (    7,763)
Miscellaneous                                             --               --
                                                  ----------        ---------
                                                 (    11,468)      (    7,763)
                                                  ----------        ---------

Income                                           (    54,456)          85,851

Provision for income tax                                  --           30,047
Realized benefit of loss carryforward                     --       (   30,047)
                                                  ----------        ---------
Net income                                    $  (    54,456)      $   85,851
                                                  ==========        =========
Earnings per share

Net income (loss):
      Basic                                          .00                 .01
      Diluted                                        .00                 .01

Weighted average number of shares outstanding     13,204,755       13,635,334
Weighted average number of shares adjusted for
  dilutive securities                             16,201,755       13,635,334

(1)Certain accounts have been reclassified to conform to current years
presentation.


The accompanying notes are an integral part of the financial statements.

BOVIE MEDICAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2002 AND 2001
(UNAUDITED)

                                                           2002           2001
Cash flows from operating activities
Net income (loss)                                     $ (  54,456)     $ 85,851
Adjustments to reconcile net income
  to net cash provided by (used in)
operating activities:
Depreciation and amortization                              70,749        87,529

Changes in current assets and liabilities:
Receivables                                              (128,238)       72,696
Inventories and repair parts                             ( 94,446)     (122,234)
Prepaid expenses                                           17,774        32,059
Accounts payable                                          112,911         1,848
Accrued expense                                          (192,006)     ( 19,419)
Other assets                                                  779      (  1,200)
Obligations to shareholders                                 2,818            --
                                                          -------       -------

Net cash provided (applied) by operating activities      (264,115)      137,130
                                                          -------       -------

Cash flows from investing activities
Increase in fixed assets                                (  82,572)     ( 28,394)
Increase in patents                                           150      ( 30,938)
Increase in deposits                                           --      (  3,874)
                                                         --------       --------
Net cash used in investing activities                   (  82,422)     ( 63,206)
                                                         --------       --------
Cash flows from financing activities
Borrowing - line of credit                                100,000        25,000
(Decrease) in obligations to shareholders                      --      ( 14,776)
(Decrease) in notes payable                              ( 17,842)     ( 12,699)
Common shares purchased                                     1,368      ( 36,690)
                                                          -------       -------
Net cash used in financing activities                      83,526      ( 39,165)
                                                          -------       -------
Net increase (decrease) in cash and cash equivalents     (263,011)       34,759

Cash and cash equivalents, beginning of period            578,354       278,662
                                                          -------       -------
Cash and cash equivalents, end of period                $ 315,343     $ 313,421
                                                          =======       =======
The accompanying notes are an integral part of the financial statements.

BOVIE MEDICAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2002 AND 2001

Cash paid during the three months ended March 31:

                                         2002               2001

Interest paid                         $ 12,367           $ 12,086
Income Taxes                             - 0 -              - 0 -

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

FOR THE THREE MONTHS ENDED MARCH 31, 2002 AND 2001

There were no non-cash  investing and financing  activities in the first quarter
of the year 2002 or 2001.

BOVIE MEDICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS

PART I. FINANCIAL INFORMATION (CONTINUED)

NOTE 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements include the accounts of Bovie Medical Corporation and its wholly owned subsidiary Aaron Medical Industries, Inc. In the opinion of management, the interim financial statements reflect all adjustments, consisting of only normal recurring items, which are necessary for a fair presentation of the results for the interim periods presented.

The results for interim periods are not necessarily indicative of results for the full year. These financial statements should be read in conjunction with the significant accounting policies and the other notes to the financial statements included in the Corporation's 1998 Annual Report to the SEC on Form 10-KSB.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates in the Preparation of Financial Statements

The preparation of consolidated financial statements, in conformity with generally accepted accounting principles, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Fair Values of Financial Instruments

Cash and cash equivalents. Holdings of highly liquid investments with maturity of three months or less, when purchased, are considered to be cash equivalents. The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair values.

Accounts receivable and accounts payable. The carrying amount of accounts receivable and accounts payable on the balance sheet approximates fair value.

Short term and long term debt. The carrying amount of the bonds and notes payable and amounts due to shareholders approximates fair value.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined principally on the average cost method. Inventories at March 31, 2002 and December 31, 2001 were as follows:

                                 March 31, 2002           December 31, 2001

  Raw materials                   $ 1,228,663               $ 1,222,349
  Work in process                     593,745                   614,342
  Finished goods                      674,524                   583,136
                                    ---------                 ---------
         Total                    $ 2,496,932               $ 2,419,827
                                    =========                 =========

BOVIE MEDICAL CORPORATION

NOTES TO FINANCIAL STATEMENTS

PART I. FINANCIAL INFORMATION (CONTINUED)

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES(CONTINUED)

Repair Parts. The Company acquired the inventory of repair parts in conjunction with the purchase of the Bovie line of generators and Bovie trade name, on May 8, 1998. The Company has maintained the inventory to service the previously sold generators. The useful life of repair parts is estimated to be five to seven years and the Company has set up an allowance for excess and obsolete parts.

As of March 31, 2002, the inventory of parts was as follows:

          Raw materials                                        $ 564,641
          Allowance for excess or obsolete parts                (247,028)
                                                                 -------
                                                               $ 317,613
                                                                 =======

Long-Lived Assets Long-lived and assets consist of property, plant and equipment, and intangible assets.

Property, plant and equipment are recorded at cost less depreciation and amortization. Depreciation and amortization are accounted for on the straight-line method based on estimated useful lives. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterment and large renewals, which extend the life of the asset, are capitalized whereas maintenance and repairs and small renewals are expenses, as incurred. The estimated useful lives are: machinery and equipment, 7-15 years; buildings, 30 years; and leasehold improvements; 10-20 years.

Intangible assets consist of patent rights and goodwill. Goodwill represents the excess of the cost of assets of the acquired companies over the values assigned to net tangible assets. These intangibles are being amortized by the straight-line method over a 5 to 20 year period.

Effective January 1, 1996, the Company adopted the Statement of Financial Accounting Standards (SFAS) No.121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of. In accordance with SFAS No.121, the Company reviews long-lived assets for impairment whenever events or changes in business circumstances occur that indicate that the carrying amount of the assets may not be recovered.

The Company assesses the recoverability of long-lived assets held, and to be used, based on undiscounted cash flows and measures the impairment, if any, using discounted cash flows. Adoption of SFAS No.121 did not have a material impact on the Company's consolidated financial position, operating results or cash flows.

Revenue Recognition and Product Warranty

Revenue from sales of products is generally recognized upon shipment to customers. The Company warrants its products for one year. The estimated future costs of warranties are not material.

BOVIE MEDICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS

PART I. FINANCIAL INFORMATION (CONTINUED)

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue Recognition and Product Warranty (continued)

Income is recognized in the financial statements (and the customer billed) when products are shipped from stock. Net sales are arrived at by deducting discounts from and adding freight out to gross sales.

Environmental Remediation

The Company accrues environmental remediation costs if it is probable that an asset has been impaired or a liability incurred at the financial statement date and the amount can be reasonably estimated. Environmental compliance costs are expenses, as incurred. Certain environmental costs are capitalized based on estimates and depreciated over their useful lives.

Earnings Per Common and Common Equivalent Share

In February 1997, the Financial Accounting Standards Board issued SFAS 128. "Earnings Per Share." SFAS 128 establishes new standards for computing and presenting earnings per share ("EPS"). Specifically, SFAS 128 replaces the previously required presentation of primary EPS with a presentation of basic EPS, requires dual presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the financial statements issued for periods ending after December 15, 1997. In 1997, the Company adopted SFAS 128.

Research and Development Costs

Only the development costs that are purchased from another enterprise and have alternative future use are capitalized and amortized over five years.

Income Taxes The Company and its wholly-owned subsidiary file a consolidated federal income tax return.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

BOVIE MEDICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS

PART I. FINANCIAL INFORMATION (CONTINUED)

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES(CONTINUED)

Non-monetary Transactions

The accounting for non-monetary assets is based on the fair values of the assets involved. Cost of a non-monetary asset acquired in exchange for another non-monetary asset is recorded at the fair value of the asset surrendered to obtain it. The difference in the costs of the assets exchanged is recognized as a gain or loss. The fair value of the asset received is used to measure the cost, if it is more clearly evident than the fair value of asset surrendered.

Stock-Based Compensation

The Company has adopted Accounting Principles Board Opinion 25 for its accounting for stock based compensation. Under this policy:

1. Compensation costs are recognized as an expense over the period of employment attributable to the employee stock options.

2. Shares issued in accordance with a plan for past or future services of an employee are allocated between the expired costs and future costs. Future costs are charged to the periods in which the services are performed. The pro forma amounts of the difference between compensation cost included in net income, and related cost, measured by the fair value based method including tax effects, are disclosed.

New Accounting Standards

In June 1997, the Financial Accounting Standards Board issued SFAS 130, "Reporting Comprehensive Income". SFAS 130 establishes standards for reporting and display of comprehensive income and its components (revenues, expenses, gains, and losses) in a full set of general purpose financial statements. Specifically, SFAS 130 requires that all items that meet the definition of components of comprehensive income be reported in a financial statement for the period in which they are recognized. However, SFAS 130 does not specify when to recognize or how to measure the items that make up comprehensive income. SFAS 130 is effective for fiscal years beginning after December 15, 1997, and early application is permitted.

Management believes the application of SFAS 130 will not have a material effect on the Company's future financial statements.

In April 1998, the FASB issued SOP 98-5, “Reporting on the Costs of Start-up Activities,” which will become effective for the Company in fiscal 2000. It requires costs of start-up activities and organization costs to be expressed, as incurred. The Company currently follows this approach and such costs have been minimal in the past.

In June 1997, the Financial Accounting Standards Board issued SFAS 131, “Financial Reporting for Segments of Business Enterprise.” SFAS 131 supersedes the “industry segment” concept of SFAS 14 with a “management approach” concept as the basis for identifying reportable segments. SFAS 131 is

BOVIE MEDICAL CORPORATION

PART I. FINANCIAL INFORMATION (CONTINUED)

New Accounting Standards (continued)

effective for fiscal years beginning after December 15, 1997 and early application is permitted. Management believes the application of SFAS 131 will not have a material effect on the Company’s future financial statements.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

The results of operations over the three months ended March 31, 2002 show increased sales and decreased profitability, as compared to the first three months of 2001. As part of operating revenues, a one time development fee of $177,500 was included which was not considered in determining the gross profit percentage for 2002. The Company's sales revenues increased by 11%, from $2,736,687 to $3,028,599. Gross profit percentage of 39% was down from 40% for the same period in 2001. The reason for the 1% decrease in gross profit was that as electrosurgical sales grew and other sales remained relatively constant, overall margins will decline since margins on electrosurgical products are less than other product margins. Gross profit increased from $1,088,358 to $1,284,067. Increased gross profit was mainly attributable to increased sales of cauteries and increased sales of electrosurgical devices. For the first quarter of 2002 and 2001, cauteries accounted for 44% of sales. For the same period, electrosurgical devices accounted for 17% and 27% of sales, respectively.

Operating salaries and related expenses had no significant increase and went from $328,404 to $329,787, in the three months ended March 31, 2002 as compared to the same period in 2001.

Research and development costs increased by 129% from $130,656 to $299,536 from the quarter ended March 31, 2001 to the quarter ending March 31, 2002. The increase was mainly attributable to engineering costs on new generator models being developed and the cost of the continued development of the J Plasma device.

Expenses for professional services increased by 20% to $98,020 in the three months ended March 31, 2002, as compared to $81,591 in the same period of the previous year. The main reason for this increase was professional fees associated with legal matters, audit of the year 2001 and consulting services.

Selling, General and Administrative expenses increased by $166,941 (35%). These expenses were $472,791 in the three month period ended March 31, 2001 as compared to $639,732 for the three months ended March 31, 2002. The increase was mainly attributable to the expense of additional personnel, the costs associated with European operations, and advertising and promotions.

Interest expense increased from $12,367 in the three months ended March 31, 2001 to $12,895 in 2002. Interest the Company pays is on its building mortgage and its line of credit.

The operating gain was $93,614 in the first quarter of 2001 as compared to an operating loss of $42,988 in the same period in 2002.

BOVIE MEDICAL CORPORATION

PART I. FINANCIAL INFORMATION (CONTINUED)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

Results of Operations (continued)

The Company had a net gain of $85,851 for the three months ended March 31, 2001 as compared to net loss of $54,456 in 2002 for the same period. The main reason for the decrease in income of $140,307 for the first quarter of 2002 from the first quarter of 2001 was an increase in selling, general and administrative expenses.

The Company sells its products mostly through distributors and independent representatives who service the distributors, both in the international market and in the USA. Distributors are contacted through response to company advertising in international medical journals or at domestic or international trade shows. The main focus for export sales has been Western Europe.

The Company has distributors in all major markets in Europe. The Company intends to continue marketing its products internationally while concentrating on major markets for increased market exposure and the introduction of new products.

During the first three months of 2002, international sales increased by 10%. These sales were $505,048, which represented 18% of total sales, while in 2002 total international sales were $555,526 and 19% of total sales. The Company expects international sales to continue to increase since it received its ISO 9000 certification in 1998.

Financial Condition

As of March 31, 2002, the amount of cash was $315,343 as compared to $313,421 at March 31, 2001. Cash applied to operating activities was $264,115 in the first quarter of 2002 as compared to $137,130 provided by operations in 2001. Net working capital of the Company on March 31, 2002 was $3,489,212 as compared to $2,480,338 in 2001.

Investing activities utilized $82,422 in cash during the first three months of 2002, compared to $63,206 in the first three months of 2001. In 2002, the Company continued its policy of investing in property, plant and equipment needed for future business requirements, including manufacturing capacity.

The Company's ten largest customers accounted for approximately 59% of net revenues for the first three months of 2002. At March 31, 2002, the ten largest receivables accounted for approximately 45% of outstanding accounts receivable.

The amount of cash provided by (utilized) financing activity was $83,526 and $(39,165) respectively, in the first three months of 2002 and 2001. The most significant financing activity in the three months ended March 31, 2002 was borrowing $100,000 additional funds on the Company credit line.

BOVIE MEDICAL CORPORATION

PART I. FINANCIAL INFORMATION (CONTINUED)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

Financial Condition (continued)

The Company believes that it has the financial resources needed to meet business requirements in the foreseeable future, including capital expenditures for the expansion of its manufacturing site, working capital requirements, and product development programs.

Outlook

The statements contained in this Outlook are based on current expectations. These statements are forward looking, and actual results may differ materially.

The Company believes that the world market for disposable medical products, such as the Company’s battery-operated cauteries, have significant growth potential since these products have not heretofore been affordable or effectively marketed outside the U.S., while we do not expect a dramatic growth in sales of cautery-related products domestically.

The Company has focused on expanding its line of electrosurgical products. Electrosurgical products sold by the Company include the standard stainless steel electrodes, the Bovie/Aaron 800 and bovie/Aaron high frequency dessicators as well as the Bovie/Aaron 1200, and Bovie/Aaron 1250, and the Bovie/Aaron 2100 high frequency generators.

From the First Quarter of 2001 to the First Quarter of 2002, the Company’s electrosurgical sales increased by 41% from $683,250 to $966,121. This increase was mainly attributable to contract purchasers and a one time promotion. With the introduction of new electrosurgical products, the Company expects electrosurgical sales to increase significantly in 2002. The Company, through its private label capability, anticipates new opportunities in the domestic market. The electrosurgical product market is larger than the Company’s traditional market and is dominated by two main competitors, ValleyLab and Conmed. The Company believes combined markets for these products exceeds $100 million worldwide, annually.

Reliance on Collaborative, Manufacturing and Selling Arrangements

The Company is dependent on certain contractual partners for manufacturing and product development. Should a collaborative partner fail to develop and manufacture products., the Company’s future business and value of related assets could be negatively affected. No assurance can be given that a collaborative partner may give sufficient high priority to the Company’s products. In addition, disagreements or disputes may arise between the Company and its contractual partners which could adversely affect production of its products.

BOVIE MEDICAL CORPORATION

PART I. FINANCIAL INFORMATION (CONTINUED)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

Liquidity and Future Plans

The Company has changed its direction from acquiring ownership interest in companies to developing and acquiring new product technology and expanding manufacturing capabilities. Continued emphasis on new product development in electrosurgery, together with new technology evaluation, illustrates our shift in direction.

In order to resume strong international sales growth and maintain its ability to sell in Europe, management has implemented and been certified as ISO9001/EN46001 quality system compliant and has been granted its CE mark (International Quality control).

The Company has a line of credit with a local commercial bank for $1,500,000. Interest on the loan is paid at the bank’s base rate. As of March 31, 2002, the Company had $250,000 outstanding on its line of credit.

The Company’s future results of operations and the other forward-looking statements contained herein particularly the statements regarding growth in the medical products industry, capital spending, research and development, and marketing and general and administrative expenses, involve a number of risks and uncertainties. In addition to the factors discussed above, other factors that could cause actual results to differ materially, are the following: business conditions and the general economy; competitive factors such as rival manufacturers’ availability of products at reasonable prices; risk of nonpayment of accounts receivable; risks associated with foreign operations; and litigation involving intellectual property and consumer issues.

The management of Bovie Medical Corporation believes that it has the product mix, facilities, personnel, and competitive and financial resources for business success, but future revenues, costs, margins, product mix and profits are all subject to the influence of a number of factors, as discussed above.

BOVIE MEDICAL CORPORATION

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Form 10-KSB for the year ended December 31, 2001, Part I, Item 3.

ITEM 2. CHANGES IN SECURITIES

There have been no changes in the instruments defining the rights or rights evidenced by any class of registered securities.

There have been no dividends declared.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

In February of 1997, the 10-year notes came due and the Company offered each bond holder 2,200 shares of common stock for their $1,000 bond and accrued interest of $550. Nineteen bondholders accepted the offer and forty-three bondholders received cash for their bonds and accrued interest. The balance of the bondholders have not redeemed their bonds or accepted the shares offered.

ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS

An annual meeting of shareholders was held on April 24, 2002, at which time the Company’s board of directors were re-elected, the Company’s auditors were appointed and the Company’s 2002 employee stock option plan was approved.

ITEM 5. EXHIBITS AND REPORTS ON FORM 8-K

A) Exhibits 28 None

BOVIE MEDICAL CORPORATION

SIGNATURES:

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bovie Medical Corporation.
(Registrant)

Date: May 15, 2002

/s/Andrew Makrides
Chief Executive Officer - Andrew Makrides,

CONSENT OF CERTIFIED PUBLIC ACCOUNTANT

We consent to the incorporation in this Quarterly Report on Form 10-QSB of Bovie Medical Corporation of our report dated May 14, 2002.

Bloom & Co., LLP
s/Bloom & Co., LLP
Hempstead, New York
May 15, 2002